Trial Profile
An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2020
Price :
$35
*
At a glance
- Drugs Lactitol (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Sponsors Braintree Laboratories
- 02 Mar 2020 According to a Sebela Pharmaceuticals media release, based on the results of 3 Phase III trials, the U.S. Food and Drug Administration (FDA) has approved Pizensy (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC) in adults.
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.
- 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.